SpectraScience Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2012
2013
2014
2015
2016
Sales/Revenue
461.30
240.00
-
6.60
5.20
Cost of Goods Sold (COGS) incl. D&A
1,229.90
364.70
175.90
166.40
360.70
Gross Income
768.60
124.70
175.90
159.80
355.50
SG&A Expense
3,552.20
2,607.00
2,529.80
2,323.60
2,088.70
EBIT
4,320.80
2,731.70
2,705.70
-
2,444.20
Unusual Expense
820.30
2,286.60
147.60
783.30
451.00
Non Operating Income/Expense
0.90
9.60
22.20
912.90
416.40
Interest Expense
3,950.60
2,294.90
1,908.10
1,021.90
1,154.90
Pretax Income
9,092.60
2,749.60
4,488.30
3,634.90
4,466.60
Consolidated Net Income
9,092.60
2,749.60
4,488.30
3,634.90
4,466.60
Net Income
9,092.60
2,749.60
4,488.30
3,634.90
4,466.60
Net Income After Extraordinaries
9,092.60
2,749.60
4,488.30
3,634.90
4,466.60
Net Income Available to Common
9,092.60
2,749.60
4,488.30
3,634.90
4,466.60
EPS (Basic)
0.09
0.02
0.03
0.02
0.01
Basic Shares Outstanding
118,764.40
160,015.50
170,237.60
216,335.10
697,694.50
EPS (Diluted)
0.09
0.02
0.03
0.02
0.01
Diluted Shares Outstanding
132,280.20
160,015.50
170,237.60
216,335.10
697,694.50
EBITDA
3,404
2,492.40
2,521.70
2,317.60
2,282.90

About SpectraScience

View Profile
Address
11568 Sorrento Valley Road
San Diego California 92121
United States
Employees -
Website http://www.spectrascience.com
Updated 07/08/2019
SpectraScience, Inc. engages in the development of a technology platform to instantly determine tissue is normal, pre-cancerous or cancerous, without the need for a physical biopsy. Its products include Optical Biopsy Forceps and WavSTAT Platform. The optical biopsy forceps are single-use attachments to the mobile console and cannot be used more than once.